IGM

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Retrieved on: 
Tuesday, April 2, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, AbbVie, Prader–Willi syndrome, Scripps Research, IGM, Horizon, Delusion, Executive, Harvey Mudd College, Patient, Acquisition, Rett syndrome, Doctor of Philosophy, Myenteric plexus, Chemistry, Research and development, Hallucination, Rare disease, Amgen, ACAD, FDA, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.
  • Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
  • “Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies,” said Steve Davis, Chief Executive Officer.
  • She joined Horizon in 2018 and served in roles of increasing responsibility that culminated at Executive Vice President, Research and Development.

IGM Financial Inc. to announce first quarter 2024 results on May 2, 2024

Retrieved on: 
Thursday, March 21, 2024
MB, Power Corporation of Canada, Webcast, PIN, Mackenzie Investments, Magazine, Calendar, TSX, IGM

WINNIPEG, MB, March 21, 2024 /CNW/ - IGM Financial Inc. (TSX: IGM) will announce its first quarter 2024 results after markets close on Thursday, May 2, 2024.

Key Points: 
  • WINNIPEG, MB, March 21, 2024 /CNW/ - IGM Financial Inc. (TSX: IGM) will announce its first quarter 2024 results after markets close on Thursday, May 2, 2024.
  • A live webcast of IGM Financial's first quarter 2024 results conference call will be available at Quarterly reporting (igmfinancial.com) on Friday, May 3 at 7am CT/8am ET.
  • James O'Sullivan, President and Chief Executive Officer, IGM Financial Inc., Luke Gould, President and Chief Executive Officer, Mackenzie Investments, Damon Murchison, President and Chief Executive Officer, IG Wealth Management and Keith Potter, Executive Vice-President and Chief Financial Officer, IGM Financial Inc., will participate in the call.
  • An archived version of the webcast will also be available on IGM Financial Inc.'s website.

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024
CD20, Progression-free survival, PFS, Myopathy, Research, Immunoglobulin M, Investment, FDA, Research and development, IGM, FOLFIRI, Myositis, Bevacizumab, Lupus, GAAP, Rheumatoid arthritis, Administration, Patient, Clinical trial, Survival, CD38, SLE, G&A, IND, Colorectal cancer, Pharmaceutical industry

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.
  • Collaboration Revenue: For the fourth quarter and year ended 2023, collaboration revenues were $0.7 million and $2.1 million, respectively, compared to $0.4 million and $1.1 million for the fourth quarter and year ended 2022, respectively.
  • Research and Development (R&D) Expenses: For the fourth quarter and year ended 2023, R&D expenses were $54.2 million and $215.5 million, respectively, compared to $45.0 million and $179.3 million for the fourth quarter and year ended 2022, respectively.
  • General and Administrative (G&A) Expenses: For the fourth quarter and year ended 2023, G&A expenses were $11.6 million and $50.1 million, respectively, compared to $11.6 million and $49.7 million for the fourth quarter and year ended 2022, respectively.

Mackenzie Investments Opens the Market

Retrieved on: 
Thursday, February 22, 2024
Multimedia, TSX, Toronto Stock Exchange, IGM, Mackenzie Investments, Head

TORONTO, Feb. 22, 2024 /PRNewswire/ - Prerna Mathews, VP, ETF Product Strategy, Mackenzie Investments, and her team joined Keith Wu, Head, Exchange Traded Products & TMX Market Center, Toronto Stock Exchange (TSX), to open the market and celebrate the launch of the Mackenzie World Low Volatility ETF (TSX: MWLV).

Key Points: 
  • TORONTO, Feb. 22, 2024 /PRNewswire/ - Prerna Mathews, VP, ETF Product Strategy, Mackenzie Investments, and her team joined Keith Wu, Head, Exchange Traded Products & TMX Market Center, Toronto Stock Exchange (TSX), to open the market and celebrate the launch of the Mackenzie World Low Volatility ETF (TSX: MWLV).
  • Mackenzie Investments ("Mackenzie") is a leading investment management firm with $195.7 billion in assets under management as of December 31, 2023.
  • Mackenzie provides investment solutions and related services to more than one million retail and institutional clients through multiple distribution channels.
  • Founded in 1967, Mackenzie is a global asset manager with offices across Canada as well as in Boston, Dublin, London, Hong Kong and Beijing.

Power Corporation Announces Executive Appointment

Retrieved on: 
Wednesday, February 14, 2024
Lakehead University, Power Corporation of Canada, Market, Corporation, Espresso, Capital market, TSX, Growth, IGM, Advisory Council, Scotiabank, Power Financial, Judgement, Business administration, Business, Economics, Power, Woman, Management

MONTRÉAL, Feb. 14, 2024 /CNW/ - Power Corporation of Canada (TSX: POW) ("Power Corporation" or the "Corporation") is pleased to announce that its Board of Directors has approved the appointment of Mr. Jake Lawrence as Executive Vice-President and Chief Financial Officer, effective March 18, 2024.

Key Points: 
  • MONTRÉAL, Feb. 14, 2024 /CNW/ - Power Corporation of Canada (TSX: POW) ("Power Corporation" or the "Corporation") is pleased to announce that its Board of Directors has approved the appointment of Mr. Jake Lawrence as Executive Vice-President and Chief Financial Officer, effective March 18, 2024.
  • "I am delighted to welcome Jake to Power Corporation," said R. Jeffrey Orr, President and Chief Executive Officer.
  • Mr. Lawrence will replace Mr. Gregory D. Tretiak, who joined Power Corporation in 2012 as Chief Financial Officer.
  • Mr. Lawrence will also serve as Executive Vice-President and Chief Financial Officer of Power Financial Corporation, a subsidiary of the Corporation.

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, EST, Conference, IGM, Immunoglobulin M, Webcast

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York.

Key Points: 
  • MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York.
  • A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations .
  • A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
PST, Webcast, Conference, IGM, Immunoglobulin M

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.
  • A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations .
  • A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

Chimerix Appoints Lisa Decker to Board of Directors

Retrieved on: 
Friday, December 29, 2023
Associate, IGM, College, Therapy, University, Business development, Holy Cross, Doctor of Philosophy, FAAN, Technology management, RN, Nektar Therapeutics, Patient, Priscilla Chan, Management

DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors.

Key Points: 
  • DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors.
  • Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service.
  • “We are delighted to welcome Lisa to the Chimerix Board of Directors.
  • “We also thank Catherine for her valuable insight and judgement to the Chimerix Board over her tenure and for the impact she has had on the company during that time.

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Retrieved on: 
Tuesday, December 5, 2023
Workforce, DR5, Sanofi, IND, Antibody, FDA, Colorectal cancer, FOLFIRI, CD20, SLE, IGM, Clinical trial, Rheumatoid arthritis, Inflammation, Investigational New Drug, Lupus, CD38, Bevacizumab, Myopathy, Myositis, Patient, Immunoglobulin M, Vaccine

In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.

Key Points: 
  • In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.
  • As a result of these actions, IGM expects to extend its cash runway into the second quarter of 2026.
  • “IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • As a part of this strategic refocusing, the Company will halt the following clinical development activities:

IGM Biosciences Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Myositis, CD38, Safety, Food, Treatment, Progression-free survival, Colorectal cancer, Acute myeloid leukemia, Myopathy, Bevacizumab, IND, Investment, Immunoglobulin G, Clinical trial, Net, Administration, Patient, Research, Lupus, Rheumatoid arthritis, FDA, Autoimmune disease, American College, G&A, Bispecific monoclonal antibody, FOLFIRI, SLE, Immunoglobulin M, GAAP, CD20, R, Antibody, Research and development, IGM, Azacitidine, Pharmaceutical industry, Vaccine, Sanofi

MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023.
  • “During the third quarter, we continued to execute across our clinical development pipeline,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • Collaboration Revenue: For the third quarter of 2023, collaboration revenues were $0.5 million, compared to $0.3 million for the same period in 2022.
  • Research and Development (R&D) Expenses: For the third quarter of 2023, R&D expenses were $54.8 million, compared to $48.2 million for the same period in 2022.